Intensity Therapeutics Inc banner

Intensity Therapeutics Inc
NASDAQ:INTS

वॉचलिस्ट प्रबंधक
Intensity Therapeutics Inc
NASDAQ:INTS
वॉचलिस्ट
कीमत: 2.7878 USD -9.19%
बाज़ार पूंजीकरण: $9.1 मिलियन

कंपनी का परिचय

कारोबार का विवरण

क्षेत्र
Health Care
उद्योग
जैव प्रौद्योगिकी
मुख्यालय
संयुक्त राज्य अमेरिका US
कर्मचारी
3
IPO की तारीख
जून 30, 2023

Intensity Therapeutics is a clinical-stage biotechnology company that develops cancer treatments designed to be injected directly into a tumor. Its approach uses the tumor itself to help trigger an immune response, with the goal of shrinking the injected tumor and helping the body attack cancer elsewhere. The company’s lead work is focused on solid tumors, where doctors and cancer centers would be the users if the therapies reach market.

The company does not sell approved drugs yet, so it does not have a traditional commercial customer base. Today it funds its work through equity financing and, if it signs them, research or licensing partnerships with larger drug companies. If its treatments are approved in the future, it would likely make money from product sales, licensing fees, and possible royalties.

What makes Intensity Therapeutics different is that it is trying to turn a tumor into part of the treatment process instead of relying only on medicines that circulate through the whole body. That could fit alongside surgery, radiation, and other cancer drugs, and it gives the company a shot at becoming a specialty oncology developer focused on local tumor treatment rather than a broad drug maker.

Intensity Therapeutics Inc निवेशक संबंध

पता
61 Wilton Road, 3rd Floor
Westport, Connecticut
United States of America

व्यवसाय खंड

Cancer drug development

Intensity Therapeutics develops injectable cancer medicines that are designed to be placed directly into tumors and studied in clinical trials for solid tumors.

ग्राहक

Cancer patients treated by oncologists, and if it partners programs out, pharmaceutical companies that license or help develop its drug candidates.

राजस्व मॉडल

It expects to make money in the future through drug sales, licensing deals, research partnerships, and milestone payments if its candidates are approved or partnered.

प्रबंधन

Mr. Lewis H. Bender M.A., M.B.A., M.S.

Founder, President, CEO & Chairman of the Board

परिचय उपलब्ध नहीं

Mr. Joseph Talamo CPA, M.B.A.

Chief Financial Officer

परिचय उपलब्ध नहीं

Mr. John Wesolowski CPA, M.B.A.

Principal Accounting Officer & Controller

परिचय उपलब्ध नहीं

Mr. James M. Ahlers

Executive Vice President of Corporate Finance

परिचय उपलब्ध नहीं

Mr. Brian Schwartz M.D.

Executive Vice President of Clinical Development

परिचय उपलब्ध नहीं

1 / 5

INTS पर रिसर्च जारी रखें

ऊपर जाएँ